All‐cause long‐term mortality: range 4 to 12 months · people with cardiogenic shock or low cardiac output syndrome
Levosimendan showed no clear difference in all‐cause long‐term mortality: range 4 to 12 months compared with dobutamine (low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 1 month · adults with cardiogenic shock or low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause long‐term mortality: range 4 to 6 months · adults with cardiogenic shock or low cardiac output syndrome
It is very uncertain whether levosimendan changes all‐cause long‐term mortality: range 4 to 6 months compared with placebo (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 30 days · adults with cardiogenic shock
It is very uncertain whether levosimendan changes all‐cause short‐term mortality: 30 days compared with enoximone (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause short‐term mortality: 28 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine‐dobutamine (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause short‐term mortality: time in hospital · adults with low cardiac output syndrome
It is very uncertain whether dopexamine changes all‐cause short‐term mortality: time in hospital compared with dopamine (very low certainty).
1 finding from 1 review
All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis caused by Staphylococcus aureus
It is very uncertain whether levofloxacin changes all‐cause mortality during hospital stay and all‐cause mortality at… compared with standard treatment (very low certainty).
1 finding from 1 review
Adverse events1 · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Congestive heart failure · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Septic embolism1 · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for cardiac surgical interventions · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Uncontrolled infection1 · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis due to Staphylococcus aureus in drug abusers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cure · people with endocarditis due to Staphylococcus aureus in drug abusers
Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside… may leads to lower cure compared with beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) (low certainty).
1 finding from 1 review
Adverse events · people with endocarditis due to Staphylococcus aureus in drug abusers
It is very uncertain whether glycopeptide (vancomycin or teicoplanin) plus aminoglycoside… changes adverse events compared with beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) (very low certainty).
1 finding from 1 review
Congestive heart failure · people with endocarditis due to Staphylococcus aureus in drug abusers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Septic embolism · people with endocarditis due to Staphylococcus aureus in drug abusers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cure4 · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found